FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:995-998 September 27, 2001 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Slamon et al. (March 15 issue)¹ show that the addition of trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor HER2 (also known as HER2/neu), to chemotherapy in women with metastatic breast cancer that overexpresses HER2 is associated with significantly better responses and longer survival than chemotherapy alone. However, cardiotoxicity is the most serious complication of trastuzumab, especially when it is administered in combination with anthracyclines.^1,2,3

We hypothesized that cardiotoxicity and antitumor efficacy may be related to specific uptake of trastuzumab in the myocardium and tumor, respectively. Twenty patients with metastatic breast cancer that expressed . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dijkers, E. C.F., Kosterink, J. G.W., Rademaker, A. P., Perk, L. R., van Dongen, G. A.M.S., Bart, J., de Jong, J. R., de Vries, E. G.E., Lub-de Hooge, M. N. (2009). Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. JNM 50: 974-981 [Abstract] [Full Text]  
• Ahlgren, S., Wallberg, H., Tran, T. A., Widstrom, C., Hjertman, M., Abrahmsen, L., Berndorff, D., Dinkelborg, L. M., Cyr, J. E., Feldwisch, J., Orlova, A., Tolmachev, V. (2009). Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine. JNM 50: 781-789 [Abstract] [Full Text]  
• OKARVI, S. M., JAMMAZ, I. A. (2009). Design, Synthesis, Radiolabeling and In Vitro and In Vivo Characterization of Tumor-antigen- and Antibody-derived Peptides for the Detection of Breast Cancer. Anticancer Res 29: 1399-1409 [Abstract] [Full Text]  
• Orlova, A., Wallberg, H., Stone-Elander, S., Tolmachev, V. (2009). On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model. JNM 50: 417-425 [Abstract] [Full Text]  
• Bird, B. R.J. H., Swain, S. M. (2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 14: 14-24 [Abstract] [Full Text]  
• van Dongen, G. A.M.S., Visser, G. W.M., Lub-de Hooge, M. N., de Vries, E. G., Perk, L. R. (2007). Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. The Oncologist 12: 1379-1389 [Abstract] [Full Text]  
• Widakowich, C., de Castro, G. Jr., de Azambuja, E., Dinh, P., Awada, A. (2007). Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. The Oncologist 12: 1443-1455 [Abstract] [Full Text]  
• Sampath, L., Kwon, S., Ke, S., Wang, W., Schiff, R., Mawad, M. E., Sevick-Muraca, E. M. (2007). Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer. JNM 48: 1501-1510 [Abstract] [Full Text]  
• Hayes, D. F., Picard, M. H. (2006). Heart of Darkness: The Downside of Trastuzumab. JCO 24: 4056-4058 [Full Text]  
• Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T.A., de Korte, M. A., Jonkman, S., Kosterink, J. G.W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., de Vries, E. G.E. (2006). Indium-111-Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. JCO 24: 2276-2282 [Abstract] [Full Text]  
• Tolmachev, V., Nilsson, F. Y., Widstrom, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., Orlova, A. (2006). 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors. JNM 47: 846-853 [Abstract] [Full Text]  
• Lunardi, G., Vannozzi, M. O., Bighin, C., Del Mastro, L., Stevani, I., Schettini, G., Venturini, M. (2003). Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann Oncol 14: 1222-1226 [Abstract] [Full Text]